Ranawaka A.P.M Perera

Dr. Ranawaka A.P.M Perera

Microbiology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
+1
orcid
FRCPath (Virology), PDipMDPath (Molecular Pathology), PDipID...

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SSSin Fun Sia
Sin Fun Sia
LYLi-Meng Yan
Li-Meng Yan
ACAlex W. H. Chin
Alex W. H. Chin
KFKevin Fung
Kevin Fung
KCKa-Tim Choy
Ka-Tim Choy
HYHui-Ling Yen
Hui-Ling Yen

4 September 2020 in Science
Verified
Journal Article
Open access
PAPrabhu Arunachalam
Prabhu Arunachalam
FWFlorian Wimmers
Florian Wimmers
CMChris Ka Pun Mok
Chris Ka Pun Mok
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
MSMadeleine Scott
Madeleine Scott
BPBali Pulendran
Bali Pulendran
Immune profiling of COVID-19 patients: Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathewet al.present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalamet al.report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions.Science, this issue p.eabc8511, p.1210

4 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ELEric Lau
Eric Lau
OTOwen T. Y. Tsang
Owen T. Y. Tsang
DHDavid S. C. Hui
David S. C. Hui
MKMike Y. W. Kwan
Mike Y. W. Kwan
WCWai-Hung Chan
Wai-Hung Chan
MPMalik Peiris
Malik Peiris
The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.

5 September 2013 in Eurosurveillance
Verified
Journal Article
Open access
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
PWPei-Gang Wang
Pei-Gang Wang
MGMokhtar Gomaa
Mokhtar Gomaa
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
GKG Kayali
G Kayali
We describe a novel spike pseudoparticle neutralisation assay (ppNT) for seroepidemiological studies on Middle East respiratory syndrome coronavirus (MERS-CoV) and apply this assay together with conventional microneutralisation (MN) tests to investigate 1,343 human and 625 animal sera. The sera were collected in Egypt as a region adjacent to areas where MERS has been described, and in Hong Kong, China as a control region. Sera from dromedary camels had a high prevalence of antibody reactive to MERS-CoV by MERS NT (93.6%) and MERS ppNT (98.2%) assay. The antibody titres ranged up to 1,280 and higher in MN assays and 10,240 and higher in ppNT assays. No other investigated species had any antibody reactivity to MERS-CoV. While seropositivity does not exclude the possibility of infection with a closely related virus, our data highlight the need to attempt detection of MERS-CoV or related coronaviruses in dromedary camels. The data show excellent correlation between the conventional MN assay and the novel ppNT assay. The newly developed ppNT assay does not require Biosafety Level 3 containment and is thus a relatively high-throughput assay, well suited for large-scale seroepidemiology studies which are needed to better understand the ecology and epidemiology of MERS-CoV.

1 June 2014 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
DCDaniel K.W. Chu
Daniel K.W. Chu
LPLeo Poon
Leo Poon
MGMokhtar Gomaa
Mokhtar Gomaa
MSMahmoud M. Shehata
Mahmoud M. Shehata
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
GKGhazi Kayali
Ghazi Kayali
We identified the near-full-genome sequence (29,908 nt, >99%) of Middle East respiratory syndrome coronavirus (MERS-CoV) from a nasal swab specimen from a dromedary camel in Egypt. We found that viruses genetically very similar to human MERS-CoV are infecting dromedaries beyond the Arabian Peninsula, where human MERS-CoV infections have not yet been detected.

1 July 2014 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
MHMaged Hemida
Maged Hemida
DCDaniel K.W. Chu
Daniel K.W. Chu
LPLeo Poon
Leo Poon
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
MAMohammad A. Alhammadi
Mohammad A. Alhammadi
MPMalik Peiris
Malik Peiris
A prospective study of a dromedary camel herd during the 2013-14 calving season showed Middle East respiratory syndrome coronavirus infection of calves and adults. Virus was isolated from the nose and feces but more frequently from the nose. Preexisting neutralizing antibody did not appear to protect against infection.